Cargando…
Driving antimalarial design through understanding of target mechanism
Malaria continues to be a global health threat, affecting approximately 219 million people in 2018 alone. The recurrent development of resistance to existing antimalarials means that the design of new drug candidates must be carefully considered. Understanding of drug target mechanism can dramatical...
Autores principales: | Calic, Petar P. S., Mansouri, Mahta, Scammells, Peter J., McGowan, Sheena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609028/ https://www.ncbi.nlm.nih.gov/pubmed/32869828 http://dx.doi.org/10.1042/BST20200224 |
Ejemplares similares
-
Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18
por: Paiardini, Alessandro, et al.
Publicado: (2015) -
Sitagliptin does not inhibit the M1 alanyl aminopeptidase from Plasmodium falciparum
por: McGowan, Sheena
Publicado: (2013) -
Design, synthesis, and biological evaluation of multiple targeting antimalarials
por: Yang, Yiqing, et al.
Publicado: (2021) -
Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery
por: Shibeshi, Melkamu Adigo, et al.
Publicado: (2020) -
Muddled mechanisms: recent progress towards antimalarial target identification
por: Edwards, Rachel L., et al.
Publicado: (2016)